228 related articles for article (PubMed ID: 10494304)
1. [Clinical researchers and pharmaceutical industry. Dangerous liaisons].
Roos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1668-71. PubMed ID: 10494304
[TBL] [Abstract][Full Text] [Related]
2. [Clinical research and pharmaceutical industry. A relationship with advantages and disadvantages].
ten Cate JW; Büller HR
Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1572-6. PubMed ID: 10443284
[TBL] [Abstract][Full Text] [Related]
3. [Clinical researchers and pharmaceutical industry].
Mees EJ
Ned Tijdschr Geneeskd; 1999 Oct; 143(44):2217. PubMed ID: 10578416
[No Abstract] [Full Text] [Related]
4. Industry sponsorship and authorship of clinical trials over 20 years.
Buchkowsky SS; Jewesson PJ
Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982
[TBL] [Abstract][Full Text] [Related]
5. [Clinical researchers and the pharmaceutical industry].
ten Cate JW
Ned Tijdschr Geneeskd; 1999 Jun; 143(26):1349-52. PubMed ID: 10416490
[TBL] [Abstract][Full Text] [Related]
6. Managing clinical grant costs.
Glass HE; Hollander K
Contemp Clin Trials; 2009 May; 30(3):221-6. PubMed ID: 19470309
[TBL] [Abstract][Full Text] [Related]
7. Implications of pharmaceutical industry funding on clinical research.
Lexchin JR
Ann Pharmacother; 2005 Jan; 39(1):194-7. PubMed ID: 15562137
[TBL] [Abstract][Full Text] [Related]
8. Conflict of interest in clinical research: direct payment to the investigators for finding human subjects and health information.
Puttagunta PS; Caulfield TA; Griener G
Health Law Rev; 2002; 10(2):30-2. PubMed ID: 15739309
[TBL] [Abstract][Full Text] [Related]
9. Conflicts of interest in dermatology.
Williams HC; Naldi L; Paul C; Vahlquist A; Schroter S; Jobling R
Acta Derm Venereol; 2006; 86(6):485-97. PubMed ID: 17106594
[TBL] [Abstract][Full Text] [Related]
10. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
James JS
AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
[TBL] [Abstract][Full Text] [Related]
11. [Dishonesty in clinical trials is expensive for the society 3].
Waldorff S
Ugeskr Laeger; 2003 Jun; 165(26):2672-3; author reply 2673-4. PubMed ID: 12886557
[No Abstract] [Full Text] [Related]
12. [Dishonesty in clinical trials is expensive for the society 2].
Lund BA; Nordby G
Ugeskr Laeger; 2003 Jun; 165(26):2672. PubMed ID: 12886556
[No Abstract] [Full Text] [Related]
13. [Dishonesty in clinical trials is expensive for the society 1].
Heslet L; Nielsen JD; Schierbeck J
Ugeskr Laeger; 2003 Jun; 165(26):2671-2. PubMed ID: 12886555
[No Abstract] [Full Text] [Related]
14. Independent medical research.
van der Meer JW; de Gier AM; van Swaaij WP; Katan MB
Neth J Med; 2007 Apr; 65(4):124-6. PubMed ID: 17452759
[No Abstract] [Full Text] [Related]
15. Policy of the American Society of Gene Therapy on financial conflict ofinterest in clinical research.
Woo SL
Mol Ther; 2000 May; 1(5 Pt 1):383-4. PubMed ID: 10979736
[No Abstract] [Full Text] [Related]
16. [The roles and responsibilities of the pharmaceutical industry].
Dejgaard A; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1676-9. PubMed ID: 12756829
[TBL] [Abstract][Full Text] [Related]
17. How pharmaceutical industry funding affects trial outcomes: causal structures and responses.
Sismondo S
Soc Sci Med; 2008 May; 66(9):1909-14. PubMed ID: 18299169
[TBL] [Abstract][Full Text] [Related]
18. Industry funded clinical trials: bias and quality.
Del Parigi A
Curr Med Res Opin; 2012 Jan; 28(1):23-5. PubMed ID: 22103762
[TBL] [Abstract][Full Text] [Related]
19. [Medical research and the pharmaceutical industry. Uneasy bedfellows or a prenuptial agreement?].
Cohen AF
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1438-42. PubMed ID: 11503309
[TBL] [Abstract][Full Text] [Related]
20. [Pharmaceutical companies as sponsors of clinical trials--advantages and limitations].
Reis LL
Rev Port Cardiol; 1992 Apr; 11(4):333-8. PubMed ID: 1632988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
